Gritstone bio, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrew R. Allen BCh, BM, MA, MRCP,
- Full Time Employees
- 231
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5959 Horton Street EmeryVille CA United States of America 94608
- IPO Date
- Sep 28, 2018
- CIK
- 0001656634
- Website
- gritstonebio.com
- Similar Companies
- Business
- Gritstone bio, Inc. Gritstone bio, Inc. (GRTS) is a clinical-stage biotechnology company that discovers, develops, manufactures and delivers next-generation immunotherapy candidates targeting cancer and infectious diseases using its proprietary Gritstone EDGE platform for neoantigen identification, self-amplifying mRNA (samRNA) vectors and chimpanzee adenovirus (ChAd); its primary oncology pipeline includes GRANITE, a personalized neoantigen-based immunotherapy in Phase 2/3 trials for microsatellite stable colorectal cancer and Phase 1/2 for other solid tumors such as gastroesophageal, non-small cell lung, bladder and head & neck cancers; SLATE, an off-the-shelf shared neoantigen immunotherapy targeting KRAS-mutant solid tumors including colorectal, pancreatic ductal adenocarcinoma, non-small cell lung, gastrointestinal, genitourinary and other cancers; infectious disease programs such as CORAL, a samRNA-based SARS-CoV-2 vaccine with pan-coronavirus potential, and an HIV therapeutic vaccine in collaboration with Gilead Sciences, Inc. Gilead Sciences, Inc.; the company also pursues multi-specific antibodies against HLA-peptide complexes on tumor cells for lung, gastric, esophageal, head & neck, squamous cell lung and cervical cancers. Founded in 2015 and headquartered in Emeryville, California, Gritstone bio operates primarily in the United States with clinical trials conducted globally and partnerships including the National Cancer Institute for KRAS-directed TCR-T cell therapy combined with SLATE-KRAS, and engagements with the Colorectal Cancer Alliance and Colontown.org for patient education. In recent developments, the company completed a $32.5 million underwritten public offering in April 2024 and appointed Stephen Webster to its board of directors; it voluntarily filed for Chapter 11 bankruptcy on October 10, 2024, followed by suspension of Nasdaq trading on October 22, 2024 with shares moving to OTC Pink under GRTSQ; on January 5, 2025, it finalized the sale of a majority of its assets to Seattle Project Corp. for $21.25 million in cash pursuant to a bankruptcy court-approved asset purchase agreement excluding certain machinery, equipment and intellectual property such as Binder IP; key executives including President and CEO Andrew Allen resigned post-sale, with Vassiliki Economides assuming the role of interim CEO alongside her CFO duties.
Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure
Penny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'Insufficient To Excite Many Investors'
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
Investors Have The Opportunity To Lead The Gritstone bio, Inc. Securities Fraud Lawsuit With The Schall Law Firm
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates
Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
GRITSTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Gritstone bio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Investors Are Invited To Take The Lead In The Gritstone Bio Inc Securities Fraud Case With The Schall Law Firm
Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights – GRTS
GRTS Investors Have The Opportunity To Lead Gritstone Bio Inc Securities Fraud Lawsuit With The Schall Law Firm
Levi & Korsinsky Notifies Gritstone bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - GRTS
GRTS LAWSUIT ALERT: Levi & Korsinsky Notifies Gritstone bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
GRTS Investors Have the Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Gritstone bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS
Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS
Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS
August 6, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - GRTS
FINAL GRTS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Gritstone bio, Inc. Investors to Join the Class Action Lawsuit!
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Gritstone bio, Inc.(GRTS) Shareholders
Levi & Korsinsky Reminds Gritstone bio, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 6, 2024 - GRTS